Alzheimer’s Disease :: Baxter & Alzheimer’s Disease Cooperative Study Group to pursue study of Gammagard Liquid
Baxter International Inc. (NYSE: BAX) and The Alzheimer?s Disease Cooperative Study (ADCS) group announced the decision to pursue a multi-center U.S. Phase III study evaluating the role of Gammagard Liquid [Immune Globulin Intravenous (Human)] (IGIV) , an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate Alzheimer?s disease.